1.82
-0.05(-2.67%)
Currency In USD
| Previous Close | 1.87 |
| Open | 1.87 |
| Day High | 1.88 |
| Day Low | 1.77 |
| 52-Week High | 1.96 |
| 52-Week Low | 0.52 |
| Volume | 7.88M |
| Average Volume | 4.81M |
| Market Cap | 595.72M |
| PE | -8.27 |
| EPS | -0.22 |
| Moving Average 50 Days | 1.53 |
| Moving Average 200 Days | 1.27 |
| Change | -0.05 |
If you invested $1000 in Ocugen, Inc. (OCGN) 10 years ago, it would be worth $11.67 as of February 28, 2026 at a share price of $1.82. Whereas If you bought $1000 worth of Ocugen, Inc. (OCGN) shares 4 years ago, it would be worth $181.64 as of February 28, 2026 at a share price of $1.82.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
GlobeNewswire Inc.
Feb 18, 2026 12:02 PM GMT
MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
GlobeNewswire Inc.
Feb 09, 2026 12:02 PM GMT
MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financi
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
GlobeNewswire Inc.
Jan 23, 2026 1:00 PM GMT
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced underwritten registered direct offering